MARKET WIREYahoo! Finance Canada • 19h ago
SI-BONE, Inc. (SIBN) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
Why SIBN Stock dropped -5.27% Today — RQD Quant Desk Flash
$21.23 -5.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $20.99
SI-BONE Inc. (SIBN) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $951.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SIBN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, SI-BONE Inc. (NASDAQ: SIBN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $21.23 (-5.27% 1D, market cap $951.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SIBN ranks #245 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SIBN compare to IRMD and IART in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), SIBN carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 79.6%, and ROIC of -10.3%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SIBN?
▼
Per SIBN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001459839), SI-BONE Inc. generated $200.9M in revenue (+20.2% YoY), -$18.9M in net income, and -$9.1M in free cash flow against $238.6M in total assets and $35.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $20.99 (-1.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SIBN)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY SIBN SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (31% of score)
20D Institutional Volume Accumulation (±8.1% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (27% of score)
Altman Z-Score 8.73 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$19.68+4.4% Next Q
44
Q2 (-2Q)Grade D$20.54+4.4% Next Q
47
Q3 (-1Q)Grade D$21.44-1% Next Q
49
CurrentGrade D+$21.23-1.1% Hist 90D α
52
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SIBN Turnaround Squeeze
While SIBN currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.50) and Max Pain ($22.29) forces dealer call-delta covering toward $24.38.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SIBN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SIBN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SIBN Stock dropped -5.27% Today — RQD Quant Desk Flash
SI-BONE Inc. (SIBN) dropped -5.27% to $21.23, trading at 85% of its 52-week range ($11.48 – $22.95). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 85% of its 52-week range ($11.48 – $22.95) with RSI-14 at 55.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.1% around $21.23 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 79.6% gross margin and $0 annual free cash flow.
Live SIBN Headlines & Catalysts
MARKET WIREStockInvest.us • 22h ago
Si-bone Stock Price Forecast. Should You Buy SIBN?StockInvest.us report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
SI-BONE (SIBN) Shares Just Moved, So What Is Going On?Yahoo Finance report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Tax withholding requires SI-BONE (SIBN) legal chief to sell 3,133 sharesStock Titan report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Si-Bone chief op & financial officer sells $94,078 in stockInvesting.com UK report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
How Packaging Seal Recall Will Impact SI BONE Stock InvestorsSimply Wall St report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
SI-BONE (SIBN) Edges Higher to $21.83 as Buyers Defend Support - Naked POChttps://www.siam.in/ report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Is SI-BONE (SIBN) Below Fair Value On Its Recall Driven Selloff?Simply Wall St report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that
MARKET WIREYahoo • 14d ago
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it wil
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SIBN)
- ✓Walkthrough of SIBN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SIBN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +59.03%▲ ASCENDING CHANNEL
2026-11-03O $22.41H $22.41L $21.23C $21.23VOL 1.25M
RES: $23.13SUP: $18.69SMA50: $19.50SMA200: $16.44
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SIBN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SIBN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SIBN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SIBN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SIBN)
Health Care Rank #245 of 1016
⚔️ IRMD vs SIBN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SIBN vs. IRMD, IART, BBNX, SGP)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, SI-BONE Inc. (SIBN) ranks #245 by composite RQD confidence (52/100, grade D+) and #363 by equity capitalization ($951.5M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with SIBN at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SIBN
ACTIVE
SI-BONE Inc. | D+ | 52/100 | — | 79.6% | -10.3% | -5.27% | $951.5M | Benchmark Subject |
| IRMD iRadimed Corporation | D+ | 55/100 | 48.8x | 76.7% | 37.7% | -10.57% | $980.5M | /irmd-vs-sibn → |
| IART Integra LifeSciences Holdings Corporation | E | 19/100 | — | 50.9% | -35.0% | -0.62% | $992.0M | /iart-vs-sibn → |
| BBNX Beta Bionics Inc. | D- | 36/100 | — | 55.4% | -22.1% | -4.72% | $910.6M | /bbnx-vs-sibn → |
| SGP SpyGlass Pharma Inc. | D- | 43/100 | — | — | -35.0% | -0.83% | $1.08B | /sgp-vs-sibn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001459839In its most recent audited fiscal period (FY2025, filed 2025-12-31), SI-BONE Inc. (SIBN) reported GAAP revenue of $200.9M (+20.2% vs. FY2024 revenue of $167.2M , and +44.7% cumulative change since FY2023) , GAAP net income of -$18.9M, operating cash flow of -$675.0K, and free cash flow of -$9.1M (+60.3% YoY). On the balance sheet, SIBN closed FY2025 with $238.6M in total assets against $35.6M in total debt (Altman Z-Score: 8.73, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $200.9M | -$18.9M | -$675.0K | -$9.1M | $238.6M | $35.6M |
| FY2024 (FY) | 2024-12-31 | $167.2M | -$30.9M | -$12.4M | -$22.9M | $230.4M | $35.5M |
| FY2023 (FY) | 2023-12-31 | $138.9M | -$43.3M | -$18.7M | -$18.7M | — | — |
3. SIBN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, SI-BONE Inc. (NASDAQ: SIBN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $21.23 (-5.27% 1D, market cap $951.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SIBN ranks #245 in composite RQD confidence.
How does SIBN compare to IRMD and IART in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), SIBN carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 79.6%, and ROIC of -10.3%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SIBN?
Per SIBN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001459839), SI-BONE Inc. generated $200.9M in revenue (+20.2% YoY), -$18.9M in net income, and -$9.1M in free cash flow against $238.6M in total assets and $35.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SIBN trading relative to its 50-day, 200-day, and 52-week technical levels?
SIBN last traded at $21.23 (-5.27% on volume of 1,249,200 shares), positioning the stock +8.87% above its 50-day simple moving average ($19.50) and +29.14% above its 200-day simple moving average ($16.44). Across its 52-week range of $11.48 to $22.95, SIBN sits at the 85.0% percentile with a 14-day RSI of 55.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.1% ($19.51 to $22.95).
ROARABLE RATING BRIEF • RQD 52/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SIBN — SI-BONE Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:31:17Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, SIBN scores 53 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The fundamental cash engine pillar scores 9 of 20 (ROIC -10.3%; FCF yield -0.9%), indicating that the business is not currently generating returns on invested capital or free cash flow in excess of its cost, which is the weakest part of the profile and the main reason the composite is low. The whale 13F flow pillar scores 17 of 20 (institutional accumulation and options positioning), the strongest pillar, suggesting institutional participation is a supportive factor even though underlying economics are weak. The insider conviction pillar scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), the lowest score in the rating, and per the news wire a Form 4-related insider sale was reported. The macro regime fit pillar scores 10 of 20 (beta 1.0; sector sensitivity), indicating market-level volatility exposure in line with the broad market. The forensic balance sheet pillar scores 14 of 20 (Altman Z 8.73; Piotroski F 6/9; Debt/Equity 0.2), which is a comparative strength: per the rating, leverage is low and the balance-sheet health indicators are favorable.
For a prospective investor, the upside drivers are the balance-sheet strength and the institutional flow signal, with the stock trading near the upper portion of its 52-week range. The rating's Sell designation reflects that these expectations are not yet supported by the cash engine. Second-order risk lies in the insider pillar: weak insider conviction combined with negative FCF implies that management-level signals do not reinforce the institutional story. This is an analytical framing, not personalized advice.
Business
Per the company profile, SI-BONE Inc. is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry.
Recent Catalysts & News Wire Analysis
Per the news wire, five items are listed, all tagged with a YELLOW signal and MARKET WIRE impact label. The items include a general market-data and forecast summary, a report that SIBN shares recently moved, an item describing a tax-withholding sale of 3,133 shares by the legal chief, an item describing a sale of $94,078 in stock by the chief operating and financial officer, and an item discussing a packaging seal recall and its effect on investors. Per the news wire, these are the primary catalysts; the packaging seal recall is a potential operational risk watch item, and the insider sales are relevant to the insider conviction pillar. Per the Butterfly Supply-Chain Graph, the supply-chain field is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the company's products, customers, and revenue model, given that the source data provides only sector classification?
- Why are P/E, forward P/E, EV/EBITDA, and EPS unavailable, and what would earnings-based valuation show?
- What is the scope and financial impact of the packaging seal recall referenced in the news wire?
- What is the size and timing of the insider sales relative to the reported holdings and the FY 2025 cash position?
- What drove the change in cash and debt for FY 2023, which is not reported in the source data?
SIBN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for SI-BONE Inc. (SIBN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago
SI-BONE, Inc. (SIBN) Stock Price, News, Quote & History Yahoo! Finance Canada report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 22h ago
Si-bone Stock Price Forecast. Should You Buy SIBN? StockInvest.us report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
SI-BONE (SIBN) Shares Just Moved, So What Is Going On? Yahoo Finance report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Tax withholding requires SI-BONE (SIBN) legal chief to sell 3,133 shares Stock Titan report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Si-Bone chief op & financial officer sells $94,078 in stock Investing.com UK report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
How Packaging Seal Recall Will Impact SI BONE Stock Investors Simply Wall St report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
SI-BONE (SIBN) Edges Higher to $21.83 as Buyers Defend Support - Naked POC https://www.siam.in/ report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Is SI-BONE (SIBN) Below Fair Value On Its Recall Driven Selloff? Simply Wall St report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SIBN Bull vs. Bear Conversation Board — What's Your Call at $21.23?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SIBN 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $24.20 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SIBN (D+ • RQD 53/100) a Buy at $22.41?
Welcome to the SIBN (SI-BONE Inc.) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $16.81 (-25.0%)
Spot @ $22.41 Pump the brakes on SIBN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SIBN, but look at what you are paying: current EV/EBITDA multiples with 79.6% gross margins. Unless SI-BONE Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $28.68 (+28.0%)
Spot @ $22.41 SIBN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SIBN, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $22.41 (52-wk range $11.48 - $22.95), any beat on forward guidance forces shorts and underweight funds to chase.